Luke Maggs

Luke Maggs

Auto-generated profile, based on publicly available information

Luke Maggs

Division of Surgical Oncology, Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 May 2024 in Clinical Cancer Research
Verified
Journal Article
Closed access
Marco VentinMarco Ventin
Marco Ventin
GCGiulia Cattaneo
Giulia Cattaneo
SAShahrzad Arya
Shahrzad Arya
JJJingyu Jia
Jingyu Jia
MGMaria Chiara Gelmi
Maria Chiara Gelmi
CFCristina R. Ferrone
Cristina R. Ferrone
Purpose: Uveal melanoma (UM) is the most common intraocular malignant tumor. Despite successful treatment of the primary tumor, about 50% of patients will recur with systemic diseases for which there are no effective treatment strategies. Here we investigated the preclinical efficacy of a chimeric antigen receptor (CAR) T-cell–based immunotherapy targeting B7-H3. Experimental Design: B7-H3 expression on primary and metastatic human UM samples and cell lines was assessed by RNA sequencing, flow cytometry, and immunohistochemistry. Antitumor activity of CAR T cells targeting B7-H3 was tested in vitro with UM cell lines, patient-derived organotypic tumor spheroids from patients with metastatic UM, and in immunodeficient and humanized murine models. Results: B7-H3 is expressed at high levels in >95% UM tumor cells in vitro and in vivo. We generated a B7-H3 CAR with an inducible caspase-9 (iCas9) suicide gene controlled by the chemical inducer of dimerization AP1903, which effectively kills UM cells in vitro and eradicates UM liver metastases in murine models. Delivery of iCas9.B7-H3 CAR T cells in experimental models of UM liver metastases demonstrates a durable antitumor response, even upon tumor rechallenge or in the presence of a significant metastatic disease burden. We demonstrate effective iCas9.B7-H3 CAR T-cell elimination in vitro and in vivo in response to AP1903. Our studies demonstrate more effective tumor suppression with iCas9.B7-H3 CAR T cells as compared to a B7-H3-targeted humanized monoclonal antibody. Conclusions: These studies support a phase I clinical trial with iCas9.B7-H3 CAR T cells to treat patients with metastatic UM.

21 August 2017 in Blood Advances
Verified
Journal Article
Open access
PDF file
LMLuke Maggs
Luke Maggs
FKFrancesca Kinsella
Francesca Kinsella
YCY. L. Tracey Chan
Y. L. Tracey Chan
SESuzy Eldershaw
Suzy Eldershaw
DMDuncan Murray
Duncan Murray
PMPaul Moss
Paul Moss
Key Points: A stem cell graft NK cell dose below 6.3 × 106 cells per kg associates with risk of disease relapse following T-cell–depleted allo-HSCT. Clinical outcomes of patients undergoing allo-HSCT may be improved by setting an NK cell threshold within donor stem cell grafts.

9 January 2025 in Cancer Immunology Research
Verified
Journal Article
Closed access
YSYi Sun
Yi Sun
LMLuke Maggs
Luke Maggs
APApekshya Panda
Apekshya Panda
SWSamuel J. Wright
Samuel J. Wright
ACAngelina M. Cicerchia
Angelina M. Cicerchia
RJRussell W. Jenkins
Russell W. Jenkins
Novel therapeutic strategies are needed to improve the efficacy of chimeric antigen receptor (CAR) T cells as a treatment of solid tumors. Multiple tumor microenvironmental factors are thought to contribute to resistance to CAR T-cell therapy in solid tumors, and appropriate model systems to identify and examine these factors using clinically relevant biospecimens are limited. In this study, we examined the activity of B7-H3–directed CAR T cells (B7-H3.CAR-T) using 3D microfluidic cultures of patient-derived organotypic tumor spheroids (PDOTS) and then confirmed the activity of B7-H3.CAR T cells in PDOTS. Although B7-H3 expression in PDOTS was associated with B7-H3.CAR-T sensitivity, mechanistic studies revealed dynamic upregulation of co-inhibitory receptors on CAR T-cells following target cell encounter that led to CAR T-cell dysfunction and limited efficacy against B7-H3–expressing tumors. PD-1 blockade restored CAR T-cell activity in monotypic and organotypic tumor spheroids with improved tumor control and upregulation of effector cytokines. Given the emerging role of TANK-binding kinase 1 (TBK1) as an immune evasion gene, we examined the effect of TBK1 inhibition on CAR T-cell efficacy. Similar to PD-1 blockade, TBK1 inhibition restored CAR T-cell activity in monotypic and organotypic tumor spheroids, prevented CAR T-cell dysfunction, and enhanced CAR T-cell proliferation. Inhibition or deletion of TBK1 also enhanced the sensitivity of cancer cells to immune-mediated killing. Taken together, our results demonstrate the feasibility and utility of ex vivo profiling of CAR T cells using PDOTS and suggest that targeting TBK1 could be used to enhance CAR T-cell efficacy by overcoming tumor-intrinsic and -extrinsic resistance mechanisms.

17 June 2026
Verified
Other
Open access
YSYi Sun
Yi Sun
LMLuke Maggs
Luke Maggs
APApekshya Panda
Apekshya Panda
SWSamuel J. Wright
Samuel J. Wright
ACAngelina M. Cicerchia
Angelina M. Cicerchia
RJRussell W. Jenkins
Russell W. Jenkins
Supplemental Figure S4 | Supporting data for ex vivo profiling of PD-1 blockade and TBK1 inhibition in combination with B7-H3.CAR-T cells using PDOTS.

17 June 2026
Verified
Other
Open access
YSYi Sun
Yi Sun
LMLuke Maggs
Luke Maggs
APApekshya Panda
Apekshya Panda
SWSamuel J. Wright
Samuel J. Wright
ACAngelina M. Cicerchia
Angelina M. Cicerchia
RJRussell W. Jenkins
Russell W. Jenkins
PDOTS patient data (accompanying Fig. 3)

17 June 2026
Verified
Other
Open access
PDF file
YSYi Sun
Yi Sun
LMLuke Maggs
Luke Maggs
APApekshya Panda
Apekshya Panda
SWSamuel J. Wright
Samuel J. Wright
ACAngelina M. Cicerchia
Angelina M. Cicerchia
RJRussell W. Jenkins
Russell W. Jenkins
Supplementary Figure S1 | Supporting data demonstrating B7-H3 expression in melanoma and other cancers.